Article
Identification of copy number alterations by array comparative genomic hybridization in patients with late chronic or accelerated phase chronic myeloid leukemia treated with imatinib mesylate.
International journal of hematology - 1 Apr 2011
Nadarajan Veera S, Phan Chin-Lee, Ang Chow-Hiang, Liang Kai-Ling, Gan Gin-Gin, Bee Ping-Chong, Zakaria Zubaidah
Abstract excerpt
The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase. This may be attributed to additional genomic alterations that accumulate during disease progression. We sought to identify such lesions in patients showing suboptimal response to IM by performing array-CGH analysis on 39...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.